Clinical Trial Update: Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating vorinostat plus capecitabine and cisplatin as first-line therapy for metastatic or recurrent gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• Vorinostat (vorinostat)

Snippet

Sponsor: Asan Medical Center | Conditions: Gastric Cancer, Histone Deacetylase Inhibitor | Phase 1, Phase 2 | Status: COMPLETED